The US FDA has granted approval to Medtronic’s Evolut FX+ transcatheter aortic valve replacement (TAVR) system for treating symptomatic severe aortic stenosis patients at all risk categories incl. extreme, high, intermediate & low
The Evolut FX+ TAVR system has a diamond-shaped frame design which increases coronary access windows providing greater catheter maneuverability required for accessing the coronary arteries across diverse patient anatomies
The system’s early US commercialization is anticipated during spring 2024 with its full launch expected during summer 2024
Ref: Medtronic | Image: Medtronic
Related Post:- Medtronic Receives the US FDA’s Approval for its PulseSelect PFA System to Treat Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
